Predicine

Executive Summary

Predicine is a privately held diagnostics company advancing GeneRADAR, a next-generation liquid biopsy platform that simultaneously analyzes circulating tumor DNA and RNA from a single blood sample. This dual-analyte approach provides comprehensive genomic and transcriptomic insights, enabling more accurate cancer detection, monitoring, and treatment selection across multiple solid tumors. The platform addresses the growing demand for minimally invasive cancer diagnostics, offering potential advantages in sensitivity and specificity compared to single-analyte tests. Currently in Phase 3 clinical development, Predicine is nearing key regulatory milestones for its lead assay. The company has not disclosed its valuation or total funding, but its late-stage status indicates significant progress and de-risking. The liquid biopsy market is competitive, yet Predicine's differentiated technology positions it well for partnerships or commercialization. Successful completion of pivotal trials and regulatory submissions will be critical for near-term value creation. Despite the lack of public pipeline details, the Phase 3 stage suggests a focused path to market.

Upcoming Catalysts (preview)

• Q4 2026Pivotal trial data readout for lead liquid biopsy assay75% success
• Q1 2027Submission of premarket approval (PMA) application to FDA70% success
• H2 2026Strategic partnership with major pharmaceutical or diagnostic company60% success